Overview of the SIRIUS clinical trial in the treatment of multiple myeloma

Overview of the SIRIUS clinical trial in the treatment of multiple myeloma

User Photo
VJHemOnc

4 years
305 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Maria-Victoria Mateos, MD, PhD from the University Hospital of Salamaca, Spain provides an overview of the SIRIUS clinical trial of daratumumab, an anti-CD38 monoclonal antibody, in the treatment of relapsed/refractory multiple myeloma (MM) patients. Approximately 100 patients received daratumumab as a single-agent, and 30% of these responded to daratumumab. Dr Mateos discusses the importance of these results, as currently treatment for this patient population is an unmet need.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.
Up Next Autoplay